Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Sponsor: I.M. Sechenov First Moscow State Medical University
Summary
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.
Official title: The Effect of Correction of Bacterial Overgrowth Syndrome in the Small Intestine on Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-09-02
Completion Date
2027-09-30
Last Updated
2024-10-22
Healthy Volunteers
No
Interventions
Rifaximin
Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
Standard HFpEF treatment
diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
Locations (1)
Moscow
Moscow, Russia